Literature DB >> 3382853

The sequential evaluation of bone scintigraphy: an analysis of revascularised bone grafts.

T Takato1, K Harii, T Nakatsuka.   

Abstract

Technetium-99m Methylene Diphosphonate (Tc-99m MDP) has often been used to assess revascularisation of bone, because positive uptake of Tc-99m MDP reflects patent anastomoses and viability of the grafted bone. However, the sequential evaluation of bone scintigraphy has seldom been reported, especially in clinical cases. We carried out sequential evaluation in 17 patients with revascularised bone grafts. In this series, intense or maximal uptake in the grafted bone was observed in the early days after surgery (1-2 weeks postoperatively), with considerable reduction after 4 weeks. Furthermore, it was found that there was no uptake of Tc-99m MDP when the anastomosed vessels were occluded, even after 6 weeks, and these three cases all developed fracture or sequestrum. We therefore believe that bone scintigraphy is reliable in the postoperative monitoring of revascularised bone for at least 4 or 6 weeks postoperatively.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3382853     DOI: 10.1016/0007-1226(88)90110-5

Source DB:  PubMed          Journal:  Br J Plast Surg        ISSN: 0007-1226


  3 in total

1.  Bone scintigraphy in the evaluation of bone grafts used for mandibular reconstruction.

Authors:  G Berding; K Bothe; K F Gratz; R Schmelzeisen; F W Neukam; H Hundeshagen
Journal:  Eur J Nucl Med       Date:  1994-02

2.  Role of (99m)Tc-methylene diphosphonate bone scan in the evaluation of the viability of the bone flap in mandibular reconstruction in patients with oromaxillofacial malignancies.

Authors:  Madhur Kumar Srivastava; Prasanth Penumadu; Dinesh Kumar; Nandini Pandit
Journal:  Indian J Nucl Med       Date:  2015 Jul-Sep

3.  Early postoperative bone scintigraphy in the evaluation of microvascular bone grafts in head and neck reconstruction.

Authors:  Jonas Schuepbach; Olivier Dassonville; Gilles Poissonnet; Francois Demard
Journal:  Head Face Med       Date:  2007-04-20       Impact factor: 2.151

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.